Development of monoclonal antibody therapy

单克隆抗体疗法的发展

• 批准号: nhmrc : 1050146
• 负责人: A/Pr Daniel Christ
• 金额: $ 30.62万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-monoclonal-antibody-therapy/112139
• 关键词: Development; monoclonal; antibody; therapy

Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.

单克隆抗体，如治疗乳腺癌的赫赛汀，已经彻底改变了癌症和炎症的治疗。2011年的销售额将超过300亿美元，它们还催生了一个不断发展的生物技术产业。我们已经产生了一种高度特异性的单克隆抗体，它在疾病模型中显示出功效。该项目将进一步推进和开发该单克隆，使我们能够在患者中开展临床研究。